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HDL is a complex and heterogeneous assembly of proteins and lipids. 
Defined by its buoyant density isolation characteristics, HDL’s com-
positional heterogeneity mirrors its functional heterogeneity, which 
includes cholesterol acceptor activity, microRNA delivery and anti-
inflammatory, anti-apoptotic, anti-thrombotic and innate immune 
functions1–6. Approximately 75% of the protein content of HDL is 
apoA1, which serves as the primary protein scaffolding on which the 
lipid cargo-carrying particle is built. The majority of apoA1 within 
the circulation is associated with HDL particles, which contain two 
or more apoA1 polypeptide chains, depending on both the degree of 
particle maturation and the protein complement associated with a 
given HDL particle. Epidemiological studies have shown an inverse 
association between circulating HDL cholesterol (HDLc) or apoA1 
levels and coronary artery disease (CAD)7. Animal studies using 
both genetic and direct infusion models have similarly shown global 
anti-atherosclerotic functions of the lipoprotein8–12. Recent clinical 
studies, however, have revealed gaps in our knowledge about HDL. 
For example, whereas several clinical intervention studies employing 
either direct infusion of HDL forms or infusion of extracorporeally 
delipidated HDL or apoA1 have shown anti-atherosclerotic effects13–15, 
several distinct classes of HDL cholesterol–elevating drugs have, in 
contrast, failed to demonstrate significant therapeutic benefit16–18. 
Moreover, Mendelian genetic studies have demonstrated that genetic 
variants that influence total circulating HDLc levels are not mechanis-
tically linked to the development of CAD19. Taken as a whole, recent 
studies underscore the complexity and evolving understanding of the 
relationship between circulating levels of HDLc and/or apoA1 and 
CAD pathogenesis.
One possible explanation of the paradox between, on the one hand, 
the well-established inverse association between HDLc levels and car-
diovascular disease (CVD), and on the other, the negative outcomes of 
recent therapeutic intervention studies raising HDLc levels, is that it is 
HDL particle function, not HDLc mass, that is more clinically relevant 
diagnostically and therapeutically. For example, measurement of the 
cholesterol efflux activity of HDL, or of apoB-depleted serum, may serve 
as a superior independent predictor of prevalent CAD risk compared 
to HDLc4. Moreover, alternative functional measures of HDL or 
its associated proteins may provide improved clinical value and 
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Recent studies have indicated that high-density lipoproteins (HDLs) and their major structural protein, apolipoprotein  
A1 (apoA1), recovered from human atheroma are dysfunctional and are extensively oxidized by myeloperoxidase (MPO).  
In vitro oxidation of either apoA1 or HDL particles by MPO impairs their cholesterol acceptor function. Here, using phage  
display affinity maturation, we developed a high-affinity monoclonal antibody that specifically recognizes both apoA1 and 
HDL that have been modified by the MPO-H2O2-Cl− system. An oxindolyl alanine (2-OH-Trp) moiety at Trp72 of apoA1 is 
the immunogenic epitope. Mutagenesis studies confirmed a critical role for apoA1 Trp72 in MPO-mediated inhibition of the 
ATP-binding cassette transporter A1 (ABCA1)-dependent cholesterol acceptor activity of apoA1 in vitro and in vivo. ApoA1 
containing a 2-OH-Trp72 group (oxTrp72-apoA1) is in low abundance within the circulation but accounts for 20% of the apoA1 
in atherosclerosis-laden arteries. OxTrp72-apoA1 recovered from human atheroma or plasma is lipid poor, virtually devoid of 
cholesterol acceptor activity and demonstrated both a potent proinflammatory activity on endothelial cells and an impaired HDL 
biogenesis activity in vivo. Elevated oxTrp72-apoA1 levels in subjects presenting to a cardiology clinic (n = 627) were associated 
with increased cardiovascular disease risk. Circulating oxTrp72-apoA1 levels may serve as a way to monitor a proatherogenic 
process in the artery wall.
prognostic efficacy5,20–24. Accordingly, current measures of HDL 
mass (either HDLc or apoA1) in the circulation do not appear to 
adequately reflect the pathobiology of a diseased artery wall. Recent 
studies of total apoA1 (both HDL-associated and lipid-poor forms) 
from human aortic tissues revealed that the biological function and 
HDL particle distribution of apoA1 within the artery wall are mark-
edly distinct from those of circulating apoA1 and HDL. Specifically, 
apoA1 in human aorta was found to be predominantly lipid poor, 
not associated with HDL, extensively oxidatively crosslinked 
and functionally impaired25. ApoA1 serves as a selective target 
(100- to 500-fold relative to total protein) for oxidative modifica-
tion by MPO-generated and nitric oxide–derived oxidants within 
the artery wall, resulting in site-specific oxidative modifications26–28. 
Parallel in vitro studies using HDL or apoA1 oxidized ex vivo by the 
MPO-H2O2-Cl− system have shown marked reductions in their vari-
ous activities—ABCA1-dependent cholesterol efflux function, leci-
thin cholesterol acyl transferase (LCAT) activity, lipid binding activity 
and non–cholesterol related activities (for example, anti-apoptotic and 
anti-inflammatory activities)—to an extent similar to that observed 
for apoA1 recovered from human lesions26,28–30. These findings, as 
well as studies demonstrating proinflammatory activities of HDL 
recovered from subjects with CAD or chronic inflammatory condi-
tions associated with CAD risk21,29,31–33, suggest that the molecular 
processes that impair apoA1 and HDL function in the artery wall may 
be diagnostic and therapeutic targets for CAD.
Here we report that Trp72 of apoA1 serves as a selective target 
for MPO-dependent oxidative modification, forming an oxindolyl 
alanine (2-hydroxy-l-tryptophan, or 2-OH-Trp; IUPAC name 
2-amino-3-(2-oxo-1,3-dihydroindol-3-yl)propanoic acid) moiety
on 20% of apoA1 recovered from human atherosclerotic lesions.
We found that both lesion and plasma apoA1 harboring this site-
specific modification were dysfunctional, with significantly impaired
cholesterol efflux acceptor activity as well as proinflammatory effects.
Moreover, data from clinical studies indicate that circulating levels of
this dysfunctional apoA1 form reflect a pathophysiological process
within the artery wall.
RESULTS
Development of an antibody specific for MPO-modified apoA1
Direct studies of HDL function in the human artery wall have been 
limited so far. To recover and study the chemical modifications and 
biological activities of HDL modified by MPO-generated oxidants 
in the artery wall, we developed immunological tools to specifically 
detect and immunopurify apoA1 modified by the MPO-H2O2-Cl− 
system. We selected this specific oxidized form of apoA1 and HDL 
because in vitro studies have demonstrated that this system readily 
inhibits the cholesterol acceptor activity of both apoA1 and HDL 
under pathophysiologically plausible conditions26,27,29. After immu-
nizing BALB/c mice with native reconstituted HDL particles (apoA1:
POPC:cholesterol, 1:100:10, mol:mol:mol) exposed to either MPO-
generated chlorinating oxidants (the MPO-H2O2-Cl− system) or 
MPO-generated nitrating oxidants (the MPO-H2O2-NO2− system), 
we generated and screened over 30,000 hybridoma cell lines 
(Supplementary Fig. 1a). To ensure that the epitopes formed would 
be those likely to be formed under (patho)physiologically plausible 
conditions, we used a low molar ratio of H2O2 to apoA1 (5:1); under 
these conditions, the content of protein-bound 3-chlorotyrosine or 
3-nitrotyrosine was within the range previously observed on apoA1
recovered from human atherosclerotic plaque26,29. We identified a
monoclonal antibody (mAb) (clone 8B5.2) that specifically recognized
both apoA1 and HDL exposed to the MPO-H2O2-Cl− system but not 
apoA1 or HDL in their native (unoxidized) forms or after exposure to 
alternative oxidant systems, including the MPO-H2O2-NO2− oxidant 
system (Supplementary Fig. 1a).
Although mAb 8B5.2 had the desired specificity, its affinity was 
too low for either efficient immunoprecipitation or use in an ELISA 
format to detect endogenous circulating levels of oxTrp72-apoA1 
(Supplementary Fig. 1b–d). We next used phage display technology 
to affinity mature (as a single-chain antibody) mAb 8B5.2 and then, 
after sequencing gain-of-function mutants, genetically engineered 
the recombinant IgG form (Online Methods). Briefly, we used human 
apoA1 exposed to the MPO-H2O2-Cl− system as the positive-selection 
bait. After the first round of positive selection, we used as negative 
selection baits both native human apoA1 and human apoA1 exposed 
to MPO-generated nitrating oxidants (Online Methods). During the 
last two affinity maturation cycles, we sequenced multiple gain-of-
function subclones and identified reproducible gain-of-function 
mutations. We then incorporated all gain-of-function mutants into a 
single clone and verified it to be functional as a high-affinity binder 
with the appropriate specificity. We then converted this ‘combined’ 
gain-of-function clone into a human-mouse chimeric IgG mAb 
(Fig. 1a–c). We termed this affinity-matured recombinant humanized 
mAb r8B5.2, which displayed a 1,600-fold enhanced affinity com-
pared to the starting (parental) mAb, attaining a KD of 1 × 10−10 M 
(Supplementary Fig. 1c). More detailed characterization studies 
confirmed that mAb r8B5.2 retained exclusive specificity for recog-
nition of apoA1 exposed to the MPO-H2O2-halide system (Fig. 1d). 
Further characterization revealed that mAb r8B5.2 had sufficient 
affinity to immunoprecipitate MPO-oxidized apoA1 and, when used 
in an ELISA format, had adequate sensitivity to detect and quantify 
apoA1 and HDL after oxidation by the MPO-H2O2-Cl− system at 
levels of oxidation comparable to those observed in plasma or serum 
(Supplementary Fig. 1d).
ApoA1 Trp72 oxidation inhibits cholesterol acceptor function
No studies to our knowledge have directly examined the functional 
importance of modification of apoA1 or HDL by MPO within human 
atheroma. Rather, the proposed in vivo effect of MPO-catalyzed 
oxidation of apoA1 and HDL—impairing the cholesterol acceptor 
activity of the lipoprotein—is based on correlative data that com-
pare the degree of oxidative modifications on apoA1 recovered from 
artery wall tissues with both the extent of oxidative modifications 
formed and the degree of ABCA1-dependent cholesterol efflux 
impairment observed in model systems ex vivo26,29. Incubation of 
apoA1 or HDL with the MPO-H2O2-Cl− system can promote oxida-
tive modification of multiple oxidant-sensitive residues of apoA1, 
including (but not limited to) each of the three methionines, each 
of the seven tyrosines and each of the four tryptophans. Oxidation 
of each of these residues has been detected by proteomics analysis 
of apoA1 or HDL recovered from human atherosclerotic lesions, yet 
debate exists about the relative abundance of various species and 
their functional importance26–29,34. We hypothesized that the epitope 
recognized by mAb r8B5.2 might be an oxidized form of tyrosine, 
methionine or tryptophan generated by the MPO-H2O2-Cl− system 
within the appropriate sequence context of apoA1. To test this idea, 
we generated recombinant mutant forms of apoA1 in which each of 
these residues was converted to a relatively nonoxidizable alternative 
amino acid of similar size and chemical properties, namely (i) each of 
the seven tyrosine residues (positions 18, 29, 100, 115, 166, 192 and 
236) was mutated to the relatively nonoxidizable phenylalanine
residue (a mutant named 7YF); (ii) each of the three methionine 
residues (positions 86, 112 and 148) was mutated to the relatively 
nonoxidizable valine residue (a mutant named 3MV); and 
(iii) each of the four tryptophan residues (positions 8, 50, 72 and 108)
was mutated to the relatively nonoxidizable phenylalanine residue 
(a mutant named 4WF). We reasoned that after exposure of the
lipoprotein to the MPO-H2O2-Cl− system, the mutant form of apoA1
no longer harboring the oxidant-sensitive residue would not be
recognized by mAb r8B5.2, whereas recombinant human (wild-type
sequence) apoA1 (rh-apoA1) would be recognized after oxidation.
Exposure of rh-apoA1, 7YF and 3MV to the MPO-H2O2-Cl− system
produced an oxidized apolipoprotein that was recognized by mAb
r8B5.2, whereas the apoA1 mutant 4WF was not recognized after
oxidation (Fig. 2a). Notably, control studies showed that all mutant
forms of apoA1 examined retained cholesterol efflux activity in their
native forms, and all forms but 4WF lost ABCA1-dependent and total
cholesterol efflux activities after exposure to the MPO-H2O2-Cl−
system (Fig. 2b). Collectively, these results suggest that one or more of
the tryptophan residues of apoA1 contribute to formation of the epitope
recognized by mAb r8B5.2 after oxidation by the MPO-H2O2-Cl−
system. Moreover, these data indicate that one or more of the tryp-
tophan residues functions as an oxidative switch for impairing the
cholesterol efflux activity of apoA1.
To identify the oxidized tryptophan residue that serves as the 
epitope recognized by mAb r8B5.2, we generated additional site- 
specific mutant forms of apoA1 in which each of the four tryptophan 
residues was converted singly to leucine (W8L, W50L, W72L and 
W108L). Alternatively, each of two of the residues was converted 
singly to phenylalanine (W72F and W108F). The MPO-oxidized form 
of each recombinant apoA1 mutant was recognized by the antibody 
except for mutants with site-specific mutation of Trp72 (Fig. 2a). 
Competition experiments using a molar excess of different oxidized 
forms of tryptophan (as free amino acids) suggested that the oxygen at 
the 2 position of the indole ring was important for epitope recognition 
(Supplementary Fig. 2). We confirmed that a 2-oxindolyl alanine, the 
2-OH-Trp moiety at Trp72 of apoA1 (oxTrp72-apoA1), is the recogni-
tion site for mAb r8B5.2 using two additional ELISA-based competition
experiments. In the first experiment, we used synthetic peptides con-
taining the sequences in apoA1 that span each of the four tryptophan
residues, in which the peptide was either in its native form (with a Trp
residue) or in its oxidized form (with a 2-OH-Trp residue) (Fig. 2c).
In the second experiment, we used a peptide spanning Trp72 in which
Trp within the peptide was in its native form or in its 2-OH or 5-OH 
indole–oxidized forms (Fig. 2d).
We next sought to determine the functional importance of Trp72 
for the cholesterol acceptor activity of apoA1 in native and MPO- 
oxidized conditions. Exposure of native recombinant human apoA1 
to increasing levels of oxidation by the MPO-H2O2-Cl− system 
at molar ratios of H2O2 to apoA1 of ~0–2 resulted in little loss of 
ABCA1-dependent cholesterol efflux activity (Fig. 2e). Mass spec-
trometry studies detected methionine sulfoxide formation at each of 
the three apoA1 methionine residues at these low levels of oxidation 
(data not shown). However, with increasing molar ratios of H2O2 to 
apoA1, there was an abrupt dose-dependent inhibition of ABCA1-
dependent cholesterol acceptor activity, with virtually no remaining 
activity at a 10:1 molar ratio (Fig. 2e). This level of oxidant expo-
sure is within the upper end of that observed within atherosclerotic 
plaques, based on the protein-bound 3-chlorotyrosine content of 
apoA1, as monitored by liquid chromatography tandem mass spec-
trometry (LC/MS/MS) analyses (Supplementary Fig. 1d). In contrast, 
the 4WF apoA1 mutant was resistant to oxidative inactivation of 
ABCA1-dependent cholesterol acceptor activity, with unaltered activ-
ity even in the presence of a 50-fold molar excess of oxidant relative 
to apoA1 (Fig. 2e), a result that is consistent with previous reports28. 
We next examined the effect of site-specific mutation of Trp72 to a 
relatively oxidant-resistant hydrophobic residue (phenylalanine or 
alanine). Either mutation resulted in an approximate 50% reduction in 
ABCA1-dependent cholesterol efflux activity at a tenfold molar excess 
of oxidant (Fig. 2e). Alternatively, apoA1 in which the other three 
tryptophan residues of apoA1 were mutated to phenylalanine (the 
3F72W mutant) showed a similar extent (~50%) of functional inacti-
vation under the same oxidant conditions (Fig. 2e and Supplementary 
Fig. 1d). Collectively these studies indicate that after exposure to the 
MPO-H2O2-halide system, oxidation of Trp72 of apoA1, yielding a 
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Figure 1 Phage display affinity maturation to form a high-affinity  
mAb specific for apoA1 oxidized by the MPO-H2O2-halide system. 
(a) Fold increase in apparent binding affinity after the indicated rounds
(1–4) of biopanning after phage display affinity maturation of the
parental mouse mAb 8B5.2 single-chain antibody (scFv). r8B5.2,
the recombinant affinity matured scFv antibody. (b) Complementarity-
determining region (CDR) DNA sequences of the original mAb 8B5.2 and
those of nine affinity-matured scFv r8B5.2 subclones identified
with lowest dissociation rate. CDRL1-3, CDRs of antibody light chain;
CDRH1-3, CDRs of antibody heavy chain. The letters indicate the
identities of the mutated amino acids and the differences between original
and affinity-matured clones. (c) The increase in apparent affinity (KD) of
the parental mAb 8B5.2 antibody and the affinity-matured scFv r8B5.2
antibody after conversion to a full-length mouse-human chimeric IgG1,
designated as r8B5.2. (d) ApoA1 or reconstituted HDL (rHDL) in native
form, or following exposure to the indicated oxidation systems, were
coated onto 96-well plates and detected with r8B5.2 (Online Methods).
OD, optical density; A450nm, absorbance at 450 nm; NA, no addition.
All data are shown as the mean ± s.d. of triplicate determinations.
2-oxindolyl alanine (2-OH-Trp) moiety, is specifically recognized 
by mAb r8B5.2 (henceforth we refer to apoA1 detected by mAb r8B5.2
as oxTrp72-apoA1 to indicate the epitope recognized). Moreover, 
oxidation of this residue is responsible for about 50% of the the loss
of cholesterol acceptor function of the oxidized lipoprotein.
Lesion apoA1 harbors a 2-OH-Trp72 group and is dysfunctional
Using this new immunological tool, we found by immunohistochemi-
cal staining that oxTrp72-apoA1 is present in human atherosclerotic 
plaques but not in normal human aorta (Fig. 3a). Staining of arterial 
tissues in parallel with an antibody to MPO revealed a staining 
pattern within plaques that was similar overall to that observed with anti–
oxTrp72-apoA1. However, whereas oxTrp72-apoA1 was not detectable 
in normal arterial tissue, we did detect weak MPO staining in this tis-
sue, with staining along the endothelial surface, within endothelial cells 
and in the narrow subendothelial space (Supplementary Fig. 3a,b). 
To further characterize oxTrp72-apoA1 in human aortic plaque, 
we performed an SDS-PAGE analysis of human aortic plaque 
homogenate (n = 5 subjects). For this analysis, we used the low-speed 
supernatant of the homogenate either before or after buoyant density 
ultracentrifugation to separate a global lipoprotein fraction (density 
(d) ≤ 1.21 g ml−1) from the lipoprotein-depleted (LPD) fraction
(d > 1.21 g ml−1) (Fig. 3b). Western blot analyses performed in
parallel using mAb r8B5.2 revealed that virtually all detectable
oxTrp72-apoA1 resided in a lipid-poor soluble form (i.e., a form that
was not lipoprotein associated) (Fig. 3c). More detailed quantification
showed that ~80% of oxTrp72-apoA1 within human aortic plaque 
homogenate was recovered in the LPD fraction and <1% was
recovered within the lipoprotein-containing fraction (Fig. 3d).
We next studied the functional characteristics of oxTrp72-apoA1 
recovered from human atherosclerotic plaques. We used an affinity 
column with covalently linked mAb r8B5.2 to isolate an apoA1 form 
harboring the 2-OH-Trp moiety at residue 72 (oxTrp72-apoA1) from 
human artery lesion homogenates. Affinity-isolated oxTrp72-apoA1 
analyzed by SDS-PAGE appeared to be at high purity: the major visible 
bands were at the molecular weights anticipated for the apoA1 mono-
mer and dimer (Fig. 3e). Mass spectrometry analyses directly detected 
tryptic peptides containing oxTrp72 (OH) (Supplementary Fig. 3c), 
and virtually no tryptic peptides harboring native (unoxidized) Trp72 
were recovered. Furthermore, mass spectrometry analyses of excised 
bands corresponding to the presumed monomer, dimer, trimer and 
higher–molecular weight crosslinked forms of apoA1 revealed that 
they all predominantly contained apoA1 (Supplementary Table 1a,b). 
We next examined the cholesterol acceptor function of oxTrp72-apoA1 
recovered from aortic lesions from multiple subjects (n = 6). Even at a 
concentration (10 µg ml−1) that was twice that used for native human 
apoA1 (used as the positive control), oxTrp72-apoA1 used as a choles-
terol acceptor showed only negligible ABCA1-dependent cholesterol 
efflux activity (Fig. 3f). Collectively, these results demonstrate that 
oxTrp72-apoA1, an MPO-modified form of apoA1 present within 
human atheroma, is predominantly non-HDL (lipoprotein) associated 
and is dysfunctional with respect to cholesterol efflux activity.
Plasma oxTrp72-apoA1 is proinflammatory
To examine the distribution of oxTrp72-apoA1 in the circulation, 
we fractionated plasma from multiple healthy subjects (six pooled 
healthy donor pools, each pool was obtained from ≥ five subjects) 
by buoyant density ultracentrifugation and determined the level of 
oxTrp72-apoA1 within each fraction. Similarly to human atheroscle-
rotic plaques, virtually all detectable oxTrp72-apoA1 in the plasma 
resided in the LPD fraction (d > 1.21 g ml−1), with only nominal levels 
recovered in the HDL fraction (d = 1.063–1.21 g ml−1) (Fig. 4a–c). 
Because of the possibility that the high shear forces of ultracentrifuga-
tion might ‘knock off ’ oxTrp72-apoA1 from the HDL, we performed 
additional studies to verify these findings. Using polyclonal antibodies 
(anti-HDL IgY) raised in chickens against human HDL (isolated from 
plasma of healthy volunteers) and covalently attached to resin, we 
immunoisolated HDL from the plasma of ten healthy (>50 years of 
age) subjects with no known CAD. Separate studies of the binding 
characteristics of the anti-HDL IgY antibody revealed preferential 
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recognition of lipidated (HDL-associated) 
apoA1 but also clear recognition of lipid-free 
apoA1 (data not shown). Recovery of HDL 
from the plasma of each subject was con-
firmed by Coomassie Blue staining of native 
gels (Supplementary Fig. 4a). Western blot analyses with mAb 10G1.5 
(termed anti-total apoA1), which recognizes equally well native and 
oxidized forms of apoA1 and HDL25, confirmed the presence of 
apoA1 within the immunoaffinity-isolated material from each subject 
(Supplementary Fig. 4b). In contrast, western blot analyses of native 
gels using mAb r8B5.2 failed to detect any bands within the HDL 
fractions even with extensive overexposure (Supplementary Fig. 4c). 
However, mAb r8B5.2 did detect bands if used in western blot analy-
ses of the samples using SDS-PAGE and with extensive overexposure 
(data not shown). Together, these results indicate that oxTrp72-apoA1, 
although present within the circulation, does not reside on an HDL 
particle to any major extent, but rather is present as a low-abundance 
lipid-poor form of apoA1 in the LPD fraction.
We next used mAb 8B5.2 to immunoaffinity isolate circulating 
oxTrp72-apoA1 from healthy subjects (multiple healthy donor pools, 
each pool was obtained from ≥ five subjects) to characterize its biologi-
cal activity. By Coomassie Blue staining, the recovered protein appeared 
to be of high purity, with the major visible bands corresponding 
to the apoA1 monomer and oxidative crosslinked dimer (Fig. 4d). By 
mass spectrometry analyses the recovered bands were confirmed to 
be apoA1, with multiple peptides containing oxidized residues (pre-
dominantly tryptophan and methionine; Supplementary Table 1c). 
Western blot analyses of the immunopurified apoA1 performed in 
parallel showed bands at the anticipated molecular weights of the 
apoA1 monomer and dimer using mAb r8B5.2 or mAb 10G1.5 
(Supplementary Fig. 4d). No detectable light or heavy chain immuno-
globulin contamination was observed under the conditions employed 
(Supplementary Fig. 4d).
We and others have shown that HDL isolated from healthy volun-
teers has anti-inflammatory effects when incubated with bovine aortic 
endothelial cells, whereas apoA1 or HDL modified by MPO ex vivo con-
verts the lipoprotein into a proinflammatory particle29. We therefore 
examined the proinflammatory properties of oxTrp72-apoA1 recov-
ered from the circulation of a nonoverlapping set of apparently healthy 
middle aged (>50 years of age) donors (n = 12). For comparison, we 
isolated total apoA1 from the same donors using polyclonal chicken 
IgY antibodies raised against native human apoA1 (Fig. 4e). After 
incubation of oxTrp72-apoA1 recovered from each subject’s plasma 
with bovine aortic endothelial cells, we observed a marked proinflam-
matory effect, as monitored by substantial increases in surface vascu-
lar cell adhesion molecule 1 (VCAM1) protein content. In contrast, 
apoA1 recovered from plasma using immunoprecipitation with the 
anti-HDL IgY antibodies, or a comparable amount of total plasma 
protein, did not elicit a proinflammatory response in the endothe-
lial cells (Fig. 4e). Moreover, immuno-isolated lipid-free (i.e., after 
organic solvent extraction) oxTrp72-apoA1 recovered from plasma 
promoted endothelial cell nuclear factor-κB (NF-κB) activation and 
nuclear localization, similarly to in vitro–oxidized lipid-free apoA1 
(using the MPO-H2O2-Cl− system) or interleukin-1 (IL-1), used as 
positive controls. In contrast to lipid-free oxTrp72-apoA1, lipid-free 
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Figure 3 Characterization of oxTrp72-apoA1 
recovered from human atherosclerotic plaque. 
(a) Immunohistochemical staining of fresh-frozen
normal and atherosclerotic sections of human
aorta. OxTrp72-apoA1 was detected with mAb
r8B5.2. Mouse IgG was used as the control.
Red, positive staining; blue, H&E counter stain.
(b,c) SDS-PAGE, protein (SYPRO ruby) staining
(b) and western blot analysis (c) of human aortic
plaque homogenate and the indicated fractions 
separated by buoyant density ultracentrifugation. 
(d) OxTrp72-apoA1 levels (as a percentage of
total apoA1) recovered in human atherosclerotic
tissue homogenate and in the lipoprotein
(d ≤ 1.21 g ml−1) and LPD (d > 1.21 g ml−1)
fractions. The data are shown as the means ± s.d.
of triplicate determinations of n = 4 subjects.
(e) SDS-PAGE followed by Coomassie
Blue (protein) staining of mAb r8B5.2–
immunopurified oxTrp72-apoA1 from human
aortic tissue (lane 2). As a positive control,
apoA1 exposed to the MPO-H2O2-Cl− system
(at a 10:1 molar ratio of H2O2 to apoA1;
Cl.apoA1), was loaded in lane 4. The ApoA1
monomer and dimer are indicated. MW,
molecular weight markers (lane 1);
IP, immunoprecipitation. Lane 3 is empty.
(f) ABCA1-dependent cholesterol efflux activity
of oxTrp72-apoA1 immunoaffinity purified 
from individual (n = 6 subjects) human aortic 
plaques. Each bar represents data from a 
different subject’s sample. Native apoA1 and 
Cl.apoA1 were used as controls. Results shown 
are mean ± s.d. of triplicate determinations.
native apoA1 isolated from plasma HDL recovered from healthy vol-
unteers did not induce NF-κB activation (Fig. 4f).
We next investigated whether formation of oxTrp72-apoA1 is 
specific to atherosclerotic plaque or if it occurs in other subacute 
inflammatory conditions, such as in a peritonitis model, in which 
inflammation is induced by the intraperitoneal (i.p.) injection of 
yeast cell-wall protein carbohydrate components (zymosan). We have 
previously shown that MPO serves as a major enzymatic catalyst for 
both protein and lipid oxidation in this model35. In human apoA1 
transgenic mice, formation of oxTrp72-apoA1 was readily detect-
able over time in both peritoneal lavage fluid (data not shown) and 
plasma, demonstrating that endogenous human apoA1 is targeted for 
post-translational modification at Trp72 during subacute inflamma-
tion (Fig. 4g). Thus, apoA1 may be oxidized at a local site of inflam-
mation, such as an atherosclerosis-laden artery wall or an inflamed 
peritoneal cavity, and then diffuse into the circulation.
OxTrp72-apoA1 has impaired HDL biogenesis activity in vivo
ABCA1 is critical for HDL biogenesis, and hepatocyte ABCA1 
expression accounts for nearly 80% of plasma HDL production36. 
Given that MPO potently inhibits the ABCA1-dependent cho-
lesterol efflux activity of apoA1 and HDL in vitro, and that our 
site-directed mutagenesis studies support a crucial role for apoA1 
Trp72 in ABCA1-dependent efflux activity (Fig. 2e), we wanted to 
test whether oxTrp72-apoA1 recovered from human plasma has an 
impaired capacity to stimulate HDL biogenesis in vivo. We first sought 
to develop an animal model that would allow us to monitor ABCA1-
dependent nascent HDL particle formation in vivo. We found that 
injection of lipid-free human apoA1 subcutaneously (s.c.) into apoA1 
knockout (KO) mice resulted in the appearance of apoA1 in the vas-
cular compartment (i.e., plasma), time-dependent increases in circu-
lating HDL particle cholesterol content and incorporation of human 
apoA1 into the HDL particle pool (Fig. 5a–d). To determine whether 
these were ABCA1-dependent phenomena, we injected lipid-free 
human apoA1 s.c. into hepatocyte-specific ABCA1 KO mice and the 
appropriate ABCA1 floxed controls36. In contrast to ABCA1 floxed 
control mice, where time-dependent increases in HDLc were noted 
and virtually all circulating apoA1 was HDL-associated, injection 
of apoA1 into ABCA1 KO mice did not result in a time-dependent 
increase in plasma HDLc levels (Supplementary Fig. 5a–c). 
Figure 4 Characterization of oxTrp72-apoA1 
recovered from human plasma. (a,b) SDS-PAGE 
followed by Coomassie Blue staining (a) or 
western blot for detection of oxTrp72-apoA1 
(using mAb 8B5.2) (b) of human plasma 
proteins before and after buoyant density 
ultracentrifugation separation into the indicated 
fractions. (c) Distribution of oxTrp72-apoA1  
in the plasma. Results shown are the  
mean ± s.d. of triplicate determinations of six 
pooled healthy donor plasma pools (each pool 
was obtained from at least n = 5 subjects).  
(d) SDS-PAGE followed by Coomassie Blue
staining of immunopurified (using mAb
r8B5.2) oxTrp72-apoA1 from plasma from
four donors. (e) Surface VCAM1 protein
expression quantified by cell-based ELISA
(Online Methods) of bovine aortic endothelial
cells (BAEC) incubated with plasma protein,
total apoA1 (recovered from plasma using
immobilized anti–total apoA1 IgY) or
oxTrp72-apoA1 (recovered from plasma using
immobilized mAb r8B5.2) from 12 individual
subjects. Serum-free media (SFM), HDL or
HDL previously exposed to the MPO-H2O2-Cl−
system (Cl.HDL, at H2O2:apoA1, 10:1, mol:mol)
were used as the vehicle, negative and positive
controls, respectively. *P < 0.05. Results shown
are mean ± s.d. of triplicate determinations, and
P values represent comparisons between subject
samples versus SFM and were determined
using the Wilcoxon and Kruskal-Wallis tests.
(f) Nuclear translocation of NF-κB was
assessed by confocal immunofluorescent
analysis of BAECs, which were untreated or 
treated with the following: IL-1 (positive control),
native apoA1 (apoA1), MPO-oxidized human
apoA1 (ox-apoA1), plasma-derived total apoA1
immunopurified using IgY to apoA1 or plasma
oxTrp72-apoA1 immunopurified using r8B5.2. 
NF-κB p65 (Glu498) staining is green and 
nuclear counterstaining (DAPI) is blue. (g) Plasma 
oxTrp72-apoA1 levels were quantified at the indicated times in human apoA1 transgenic (hapoA1-Tg) mice injected i.p. with zymosan (t = 0). Quantification 
was performed by sandwich ELISA using mAb r8B5.2 as the capture antibody and mAb 10G1.5 (anti–total apoA1) as the detection antibody (Online Methods). 
Results shown are mean ± s.d. of triplicate determinations from n = 3 animals.
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Moreover, in ABCA1 KO mice, virtually no human apoA1 appeared 
within the HDL fraction (Supplementary Fig. 5a–c).
Using this in vivo model of ABCA1-dependent HDL biogenesis, we 
next tested whether oxTrp72-apoA1 recovered from human plasma 
was indeed dysfunctional in vivo. Injection of apoA1 KO mice s.c. 
with equivalent amounts of either lipid-free native human apoA1 or 
immunoaffinity-isolated oxTrp72-apoA1 resulted in comparable time-
dependent appearances of total apoA1 in the circulation (Fig. 5a). 
However, whereas s.c. injection of native human apoA1 induced 
time-dependent increases in HDLc levels over a short period of 
time (2 h), injection of oxTrp72-apoA1 did not increase HDLc levels 
(despite being present in the vascular compartment), and reproduc-
ibly even slightly reduced HDLc levels (Fig. 5b). Native human apoA1 
appearing in the circulation resided entirely within HDL particles 
(Fig. 5c), whereas oxTrp72-apoA1 remained predominantly within 
the LPD fraction (Fig. 5d). Thus, oxTrp72-apoA1 recovered from 
human plasma is deficient in ABCA1-dependent HDL biogenesis 
activity in vivo.
We next tested whether an apoA1 form in which Trp72 is mutated 
to phenylalanine (72WF-apoA1), which is resistant to MPO-catalyzed 
oxidative inactivation in vitro (Fig. 2e), demonstrates improved bio-
logical function relative to native human apoA1 after oxidation. We 
examined native wild-type recombinant human apoA1 (rh-apoA1) 
and 72WF-apoA1 for in vivo HDL biogenesis activity in both their 
native and MPO-oxidized forms. After s.c. injection of either the native 
or oxidized forms of rh-apoA1 or 72WF-apoA1 into apoA1 KO mice, 
comparable total plasma apoA1 levels were observed (Supplementary 
Fig. 6a). Within 2 h after injection of native rh-apoA1, we observed 
time-dependent increases in plasma HDLc levels, consistent with de 
novo HDL biogenesis (Fig. 5e). In contrast, injection of rh-apoA1 
exposed to the MPO-H2O2-Cl− system (apoA1:H2O2, 10:1) led to 
a time-dependent decrease (within 2 h) in HDLc levels (Fig. 5e). 
Injection of native 72WF-apoA1 led to a similar increase in HDLc 
levels compared to native rh-apoA1, but injection of oxidized 72WF-
apoA1 did not lead to a reduction in HDLc levels (Fig. 5e). More 
substantial differences between the behavior of rh-apoA1 and 72WF-
apoA1 were revealed by examination of the HDL particle distribution 
of the injected apoA1 (Fig. 5f and Supplementary Fig. 6b). Whereas 
most of the injected oxidized rh-apoA1 failed to become incorporated 
into HDL particles, virtually all of the injected oxidized 72WF-apoA1 
Figure 5 oxTrp72-apoA1 has impaired function 
in vivo and is associated with CVD. (a–d) Total 
apoA1 levels (a), HDLc levels (b) and apoA1 
distribution within the HDL and lipoprotein-
depleted fractions (LPDF) of plasma (c,d) 
quantified at the indicated times in apoA1 
KO mice (6–8 weeks old) injected s.c. with 
equivalent amounts of apoA1 or oxTrp72-apoA1 
(Online Methods). Data shown are mean ± 
s.d. (a,b) and mean ± s.e.m. (c,d) of triplicate
determinations of n = 3 mice in each group.
(e) Plasma HDLc levels in apoA1 KO mice
injected s.c. with equivalent amounts of  
rh-apoA1, 72WF or their corresponding  
MPO-oxidized forms (formed at H2O2:
apoA1, 10:1, mol:mol). Plasma HDLc levels 
were determined before and 2 h after apoA1 
injections. Each symbol shown represents an 
individual mouse. (f) apoA1 distribution in 
plasma between the HDL (d = 1.063–1.21 g ml−1) 
and LPD (d ≥ 1.21 g ml−1) fractions expressed 
as a percentage of the total apoA1 in plasma 2 
h after apoA1 injection. Data shown are mean 
± s.d. of triplicate determinations of n = 3 mice
in each group. (g) Levels of oxTrp72-apoA1 
(relative to total apoA1) in plasma and human 
aortic plaque homogenate from the indicated 
number of subjects. Levels were quantified 
by sandwich ELISA using mAb r8B5.2 as the 
capture antibody and mAb 10G1.5 (anti–total 
apoA1) as the detection antibody. Wilcoxon and 
Kruskal-Wallis tests were used to calculate P 
values. The value shown (bar) is the mean ± s.d. 
(h) Box-and-whisker plots of oxTrp72-apoA1
concentration and the ratio of oxTrp72-apoA1 to 
total apoA1 (as a percentage) within the plasma 
among subjects (n = 627) within the cohort 
stratified by the presence versus absence 
of either CAD or CVD as indicated.  
The box-and-whisker plots show percentiles  
(10%, 25%, 50%, 75% and 90%). Wilcoxon 
and Kruskal-Wallis tests were used to calculate 
P values. (i) Odds ratio (symbols) and 95% confidence intervals (CI; line or arrow) for CVD risk (unadjusted and after multilogistic regression analyses). 
The fully loaded model included oxTrp72-apoA1, apoA1, age, sex, hypertension, diabetes, smoking, HDLc, circulating low-density lipoprotein (LDLc), 
triglycerides, high-sensitivity C-reactive protein, hemoglobin A1C (HgbA1c), MPO and lipid lowering medicine.
a
apoA1
oxTrp72-
apoA1
30
21
Time (h)
0
15
ap
oA
1 
(m
g 
dL
–1
)
0
b apoA1
oxTrp72-
apoA1
40
20
H
D
Lc
 (
m
g 
dL
–1
)
0
21
Time (h)
0
c HDL
LPDF
apoA1
injection
10
5
A
po
A
1 
in
 e
ac
h
fr
ac
tio
n 
(µ
g)
0
21
Time (h)
0
d
HDL
LPDF
oxTrp72-apoA1
injection
10
5
A
po
A
1 
in
 e
ac
h
fr
ac
tio
n 
(µ
g)
0
21
Time (h)
0
i
oxTrp72-apoA1
oxTrp72-apoA1/apoA1
Unadjusted
Adjusted
Unadjusted
Adjusted
Unadjusted
Adjusted
Unadjusted
Adjusted
0 1 2
Odds ratio (95% Cl)
3 4 5 6
HDLc
CVD
13.0
9.6
apoA1
h P < 0.05
ox
T
rp
72
-a
po
A
1 
(n
M
)
7.0
3.5
0
No
n-
CA
D
CA
D
No
n-
CV
D
CV
D
P < 0.05 P < 0.001
O
xT
rp
72
-a
po
A
1/
ap
oA
1 
(µ
m
ol
 m
ol
–1
)
160
80
0
No
n-
CA
D
CA
D
No
n-
CV
D
CV
D
P < 0.001
g
1,000,000
1,000
100
10,000
100,000
10
1
0.1
(n = 627)
Human
plasma
(n = 10)
Human
aortic
plaque
204,098 ±
84,138
(20.4%)
71 ± 71
(0.007%)
ox
T
rp
72
-a
po
A
1/
ap
oA
1
(µ
m
ol
 m
ol
–1
)
P < 0.001e P < 0.05
P < 0.05
30
0 2 0 2 0 2 0 2
20
10
H
D
Lc
 (
m
g 
dL
–1
)
0
rh
-a
po
A1
ox
-rh
-a
po
A1
72
W
F
ox
72
W
F
Time (h):
Injection:
P < 0.05
P < 0.51
f
2 2 2 2 2 2 2 2
ap
oA
1 
pe
rc
en
ta
ge
in
 fr
ac
tio
ns
 (
%
)
100
75
25
50
0
rh
-a
po
A1
ox
-rh
-a
po
A1
72
W
F
ox
72
W
F
Time (h):
Injection:
HDL LPDF
did so (Fig. 5f). Thus, site-specific mutation of Trp72 into the oxidant-
resistant residue phenylalanine produced a mutant form of apoA1 
that was protected from oxidative loss of HDL biogenesis activity, 
consistent with in vitro data demonstrating an improved interaction 
with ABCA1 (Fig. 2e).
OxTrp72-apoA1 is abundant in human atheroma and predicts CVD 
To quantify the content of oxTrp72-apoA1 in human plasma and 
aortic atherosclerotic plaque homogenate, we developed a sand-
wich immunoassay. In this assay, mAb r8B5.2 was used as the cap-
ture antibody, and mAb 10G1.5 was used as the detection antibody 
(mAb 10G1.5 recognizes native and oxidized forms of apoA1 and 
HDL to comparable extents, and also recognizes lipid-free and 
HDL-associated apoA1 to comparable extents). We examined 
sequential consenting subjects (n = 627) undergoing elective risk-
factor evaluation and cardiac examination in an outpatient preven-
tive cardiology clinic. Examination of the clinical and demographic 
characteristics of the cohort (Supplementary Table 2a) showed 
that 35% of subjects had clinical evidence of CVD. Quantification 
of plasma oxTrp72-apoA1 and total apoA1 levels in the cohort 
revealed substantial variability among subjects. On average, only 
0.007% of apoA1 in plasma harbored the 2-OH-Trp72 moiety 
(Fig. 5g). In contrast, oxTrp72-apoA1 represented 20% of total 
apoA1 within atherosclerotic plaque–laden aorta (n = 10) (Fig. 5g  
and Supplementary Fig. 7a,b), and is thus greater than 1,000-fold 
more abundant (relative to total apoA1) in plaque compared to 
plasma. For illustrative purposes, we also examined plasma from a 
random sampling of subjects from the cohort without (n = 8) or with 
(n = 8) CVD using SDS-PAGE and either Coomassie Blue staining for 
protein or western blot analyses using each of the mAbs used in the 
sandwich immunoassay (Supplementary Fig. 7c–e). Of note, both 
capture (mAb r8B5.2) and detection (mAb 10G1.5) antibodies in the 
ELISA recognized a single major band in plasma at the molecular 
weight of apoA1 monomer, although with overexposure, bands were 
also notable at molecular weights corresponding to apoA1 dimer and 
higher molecular weight oxidative cross-linked multimers.
Over the entire cohort, we observed the expected inverse correla-
tions of HDLc and apoA1 levels with CAD and CVD (Supplementary 
Fig. 7f–i). In contrast, the absolute concentration of oxTrp72-apoA1 
and the ratio of oxTrp72-apoA1 to total apoA1 was significantly 
higher in subjects with either CAD or CVD compared to their corre-
sponding controls (i.e., non-CAD or non-CVD, respectively; Fig. 5h). 
Logistic regression models with adjustment for traditional cardiac risk 
factors (age, sex, hypertension, diabetes mellitus, current or former 
smoker, LDLc and HDLc), triglycerides, apoA1, high-sensitivity 
C-reactive protein, MPO, HbA1c and history of lipid-lowering medi-
cine were used to estimate odds ratio and 95% confidence interval
for CVD or CAD. Higher levels of circulating oxTrp72-apoA1 (both
absolute concentration and as a ratio relative to total apoA1) were
independently associated with increased CAD and CVD risk, par-
ticularly when comparing the fourth quartile to the first (Fig. 5i and
Supplementary Table 2b). The positive associations with increased
CAD or CVD risk remained significant even after adjustments for
traditional CVD risk factors, apoA1, MPO and high sensitivity 
C-reactive protein levels, and the use of lipid-lowering medication
(Fig. 5i and Supplementary Table 2b). We evaluated the improvement
in logistic regression model (Online Methods) performance intro-
duced by the inclusion of oxTrp72-apoA1 using the net reclassification
index and the integrated discrimination improvement. Though there
was no significant gain in the area under the curve (i.e., the receiver
operating characteristic curve), inclusion of oxTrp72-apoA1 in the 
fully adjusted model resulted in a significant improvement in risk esti-
mation based on the net reclassification index (CAD: 4.1%, P < 0.001; 
CVD: 5.9%, P < 0.001) and the integrated discrimination improve-
ment (20% for both CAD and CVD, P < 0.001). Of note, the prognostic 
values of HDLc and apoA1 each demonstrated the expected inverse 
association with CVD and CAD risk (Fig. 5i and Supplementary 
Table 2b). We also performed comparisons of the odds ratios (and 
95% confidence intervals) for oxTrp72-apoA1 plasma concentration 
versus traditional risk factors for CVD and found that the odds ratios 
observed using oxTrp72-apoA1 concentrations as a continuous vari-
able were comparable in magnitude to numerous established risk fac-
tors within the cohort (Supplementary Table 2c).
DISCUSSION
The atheroprotective role of HDL has been questioned because of 
both recent failures of multiple HDLc-raising drugs and Mendelian 
randomization studies showing that genetic variants that control 
HDLc levels are not associated with risk of CAD16–18,37. Yet there 
is overwhelming preclinical data showing that apoA1 has anti- 
atherosclerotic effects1,3,5,6. This apparent contradiction has spurred 
interest in better understanding the role of the HDL particle in 
human CAD. Ideally, HDL in the circulation should be monitored 
in a manner that reflects its function within the artery wall. Studies 
thus far have shown that apoA1 recovered from human atheroma is 
highly oxidized, crosslinked, dysfunctional (with respect to choles-
terol efflux and LCAT activities) and lipid poor, as it is not associated 
with an HDL particle25. Despite the recognition that apoA1 in lesions 
is heavily oxidized, direct functional interrogation of a structurally 
specific oxidative modification on apoA1 recovered from the artery 
wall has not been reported, to our knowledge. Our present studies 
identify the structural basis of an abundant dysfunctional form of 
apoA1 and HDL within the artery wall: MPO-catalyzed site-specific 
oxidation of Trp72 of apoA1 forming an oxindolyl alanine (2-OH-Trp) 
moiety. We found that this form of apoA1 is highly prevalent in 
human atheroma, accounting for one in five apoA1s within the lesion. 
Notably, the oxidized apoA1 form oxTrp72-apoA1 was minimally 
associated with HDL particles, with virtually all oxTrp72-apoA1 in 
both the artery wall and plasma recovered as a lipid-poor form. Thus, 
isolation of HDL-like particles recovered from human arterial lesion 
homogenates using buoyant density ultracentrifugation, an approach 
used by some researchers when studying apoA1 from lesions38,39, 
misses the vast majority of this abundant modified form of apoA1 
in vivo. We also found that lipid-free oxTrp72-apoA1 recovered from 
human plasma, like lipid-poor apoA1 modified by the MPO-H2O2-Cl− 
system, is proinflammatory, capable of inducing endothelial cell NF-κB 
activation and nuclear localization, as well as surface expression of 
VCAM1 protein, an adhesion protein with known proatherogenic 
function40. Whether differences in lipid binding capability of oxidized 
as compared to native apoA1 forms contribute to pathophysiological 
functions is unclear.
An overall scheme of our findings is illustrated in Figure 6a. 
Circulating HDL readily diffuses into the artery wall. Within 
atherosclerotic lesions, MPO is enriched and promotes site-specific 
oxidative modification of apoA1 at residue Trp72. The results of 
site-directed mutagenesis studies show that this residue is essential for 
the ABCA1-dependent cholesterol efflux activity of apoA1 in vitro, 
and animal model studies with the 72WF-apoA1 mutant demonstrate 
the importance of this residue in loss of apoA1 association with 
HDL particles in vivo after MPO-catalyzed oxidation. Recovery of 
would not anticipate that oxTrp72-apoA1 levels in the circulation 
could serve as a specific indicator of atherosclerosis. Nonetheless, 
multilogistic regression analyses within the clinical cohort examined 
demonstrate that elevated levels of oxTrp72-apoA1 are associated 
with CAD and CVD risk, associations that remain statistically sig-
nificant after adjustments for multiple traditional risk factors, 
includ-ing apoA1, MPO and other markers of inflammation. It is 
possible that the proinflammatory activity of oxTrp72-apoA1 may 
render it proatherogenic, such that elevated levels of oxTrp72-apoA1 
may con-tribute to the well-recognized phenomenon of increased 
CVD risk during chronic inflammatory conditions. However, 
further studies are needed to test this intriguing hypothesis.
Our studies suggest that formation of oxTrp72-apoA1 occurs 
within the protected environment of the subendothelial space (Fig. 
6a),  and that this oxidized form of apoA1 then diffuses out of the 
artery wall to reach the intravascular compartment. MPO has been 
shown to accumulate within the subendothelial compartment47 and 
has been mechanistically linked to the formation of vulnerable 
plaques by mechanisms including catalytic consumption of nitric 
oxide48,49, activation of matrix metalloproteinase pathways50 and 
promotion of endothelial cell apoptosis and superficial erosions 
within culprit  lesions51. Indeed, MPO is currently being examined 
as a poten-tial target for functional imaging of vulnerable 
plaque52,53 and as a pharmacological target for treatment of CVD. 
The present studies suggest that quantification of oxTrp72-apoA1 
within the circulation may serve as a gauge of proatherosclerotic 
processes that impair apoA1 and HDL function in the artery wall 
and that oxTrp72-apoA1 may serve as a new diagnostic and 
therapeutic  target in CAD.
METHODS
Methods and any associated references are available in the online 
version of the paper.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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Figure 6 Formation of a dysfunctional apoA1 form, oxTrp72-apoA1,  within 
human atherosclerotic lesions. (a) Schematic summary illustrating the 
formation of an abundant dysfunctional apoA1 form in human atheroma 
generated by MPO (see text for details). EC, endothelial cell; SMC, smooth 
muscle cell. (b) Model of spherical HDL demonstrating 
the close spatial proximity between the MPO binding site on one apoA1 
chain and Trp72 on the contralateral anti-parallel apoA1 chain. There are 
three apoA1 chains in the reconstituted spherical HDL shown. Each chain 
has a Trp72 that is in close spatial proximity to an MPO binding site on a 
contralateral apoA1 chain (labels A, B and C indicate the general locations 
of oxTrp and corresponding closest MPO binding site). Shown are the 
longest (18 Å) and shortest (6 Å) predicted distances between oxTrp72 and 
the MPO binding site on the contralateral apoA1 among the three apoA1 
chains43. The apoA1 polypeptide chains are depicted in red and slate gray. 
Trp72, yellow; MPO interaction site with apoA1, light blue. 
apoA1 from lesions using a mAb specific for oxTrp72-apoA1 
revealed  virtually no detectable ABCA1-dependent cholesterol 
acceptor  activity and potent proinflammatory activity. Notably, 
injection of apoA1 harboring the 2-OH-Trp moiety into apoA1 KO 
mice con-firmed that this apoA1 form is impaired in HDL 
biogenesis activity, as it failed to elicit an increase in circulating 
HDLc levels or appear on HDL particles.
The MPO-H2O2-Cl− oxidative system generates a 2-oxindolyl 
alanine (2-OH-Trp) moiety on apoA1 at Trp72, and our detailed 
structural analyses reveal a remarkable specificity for both oxida-tion 
at Trp72 and on the indole ring at the 2 position. The selective 
targeting of the Trp72 site of apoA1 by the MPO system, but not by 
alternative oxidation systems, appears to have a structural basis: the 
close proximity between the MPO binding site on the antiparallel 
apoA1 chain and Trp72 of apoA1 (Fig. 6b). It is widely believed 
that apoA1 within HDL is configured predominantly as antiparallel 
amphipathic alpha-helical chains27,41–45. We recently used small-
angle neutron scattering with contrast variation to directly visualize 
the protein shape of apoA1 within spherical HDL, the most abun-
dant form of HDL in the circulation44. Coupled with crosslinking 
mass spectrometry studies and molecular modeling, we developed a 
model of apoA1 within spherical HDL44. In this model, the dis-tance 
between Trp72 and the MPO binding region on apoA1, which was 
identified by hydrogen-deuterium exchange (residues Ala190–
Leu203)26, is remarkably short, ranging between a maximum pre-
dicted length of 18 Å to a minimal distance of only 6 Å (Fig. 6b). 
Moreover, the predicted distance between Trp72 of one apoA1 chain 
and the MPO binding site on the adjacent apoA1 chain in nascent  
HDL shows a similarly short distance (14 Å) (Supplementary  
Fig. 8). The oxidant formed by the MPO-H2O2-Cl− system, HOCl, is 
highly reactive and is scavenged rapidly by the first susceptible target 
it encounters (which is virtually any amino acid, though 
methionine, cysteine, histidine, tryptophan, lysine and tryosine are 
the most reactive46). In all structural models of HDL reported, the 
MPO binding site and Trp72 are separated by a short diffusion 
distance, which probably contributes to the selective targeting of 
Trp72 for oxidative modification by MPO (Fig. 6b).
Although oxTrp72-apoA1 is highly enriched within the athero-
sclerotic plaque, no detectable immunostaining with mAb 8B5.2 was 
observed within normal aortic tissue. Thus, within the artery wall, 
MPO-dependent oxidative modification of apoA1 appears to be 
highly correlated with the atherosclerotic disease process. However, 
we did observe an increase in circulating oxTrp72-apoA1 levels in a 
mouse model of peritonitis. Thus, apoA1 may be oxidized at a local 
site of inflammation, whether the artery wall or an inflamed 
peritoneal cav-ity, and then diffuse into the circulation. Based on 
these results, we 
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ONLINE METHODS
Materials. Human MPO was isolated and characterized as described54. 
[3H]cholesterol was obtained from Amersham Biosciences (Piscataway, NJ). 
l-[13C6]tyrosine, l-[13C9,15N1]tyrosine, [13C6,15N1]leucine, l-[13C9,15N1]-
phenylalanine and l-[13C5,15N1]valine were purchased from Cambridge 
Isotope Laboratories Inc. (Andover, MA). A mouse immunoglobulin isotyping 
kit was obtained from GIBCO BRL (Life Technologies GmbH). Trypsin was 
from Promega (Madison, WI), and all cell lines were from the American Type 
Culture Collection (Rockville, MD). 5-hydroxy-l-tryptophan was purchased 
from MP Biomedicals (Solon, OH). 6-hydroxyindole and 7-hydroxyindole 
were purchased from Chem-Impex International Inc (Wood Dale, IL). All 
peptides were synthesized by the CS Bio Company, Inc. (Menlo Park, CA). 
All other reagents were obtained from Sigma-Aldrich (St. Louis, MO) unless 
otherwise specified.
General procedures. All study protocols were approved by the Institutional 
Review Board of the Cleveland Clinic, and all subjects gave written informed 
consent. All mouse studies were performed under protocols approved by the 
Institutional Animal Care and Use Committee at the Cleveland Clinic.
Circulating HDL and plasma-derived purified apoA1 were obtained from 
healthy volunteer donors as previously described55. Protein content was deter-
mined by the Markwell-modified Lowry protein assay56 with BSA as the stand-
ard. Recombinant human apoA1 was generated in an Escherichia coli expression 
system and isolated by sequential column chromatographies as described26,57. 
Briefly, rh-apoA1 and mutants were expressed in E. coli strain BL21 (DE-3) 
pLysS. All mutations were made using the QuickChange Mutagenesis Kit 
(Stratagene, La Jolla, CA) and confirmed by DNA sequencing. 4WF and 4WL 
represent recombinant human apoA1 in which all tryptophans (residues 8, 50, 
72 and 108) were converted to phenylalanine or leucine. W8L, W50L, W72L, 
W72F, W108F and W108L are recombinant human apoA1 mutants with the 
indicated single tryptophan mutation. 3MV is an apoA1 mutant in which all 
three methionines (at residues 86, 112 and 148) were mutated to valine. 7YF 
is an apoA1 mutant in which all seven tyrosines (at residues 18, 29, 100, 115, 
166, 192 and 236) were converted to phenylalanine. Reconstituted nascent 
HDL was prepared using the modified sodium cholate dialysis method58 at 
an initial molar ratio of 100:10:1 of POPC (1-palmitoyl-2-oleoyl-sn-glycero-
3-phosphocholine):cholesterol:apoA1. To remove all endotoxin from purified 
recombinant apoA1, all mutants were lipidated (using POPC:apoA1, 100:1 mol:
mol), forming nascent HDL, and then delipidated by organic solvent extraction 
for six consecutive rounds. Endotoxin levels in all recombinant apoA1 were 
confirmed to be nominal (<0.5 EU mg−1 ml−1 protein) by Limulus amoebocyte 
lysate assay (Charles River Laboratories, Wilmington, MA). The concentration 
of apoA1 mutants was determined by both their predicted extinction coeffi-
cient at 280 nm and amino acid composition analyses after HCl hydrolysis (in 
the pure form). The accuracy of the protein concentrations of isolated pure 
apoA1 mutants was determined by stable isotope dilution LC/MS/MS analyses 
on an AB SCIEX 5000 triple quadrupole mass spectrometer using synthetic 
l-[13C9,15N1]tyrosine, [13C6,15N1]leucine, l-[13C9,15N1]phenylalanine and 
l-[13C5,15N1]valine as internal standards and the predicted sequence of the 
mutant. The concentration of H2O2 was determined spectrophotometrically 
(ε240 = 39.4 M−1 cm−1). HOCl was added as NaOCl to the buffered reaction 
mixtures. The concentration of NaOCl was determined spectrophotometrically 
(ε292 = 350 M−1 cm−1). Peroxynitrite (ONOO−) was quantified spectrophoto-
metrically (ε302 = 1,670 M−1 cm−1). Protein-bound ClTyr was quantified by 
stable isotope dilution LC/MS/MS analyses using synthetic 3-Cl[13C6]tyrosine 
and l-[13C9,15N1]tyrosine as internal standards on an AB SCIEX 5000 triple 
quadrupole mass spectrometer as described26,35. Monoclonal antibodies spe-
cific for apoA1 or MPO-modified apoA1 (exposed to the MPO H2O2 Cl− or 
MPO H2O2 NO2− system; H2O2:apoA1 molar ratio of 5:1) were generated using 
hybridoma technology59. The cholesterol efflux (ABCA1-dependent and total) 
activity of apoA1 was determined as described26. Specifically, RAW264.7 cells 
(ATCC, Rockville, MD) were treated with 2 µg ml−1 of apoA1(Fig. 2b,e) or 
the amount of proteins indicated in Figure 3f for 6 h. Efflux to the cholesterol 
acceptor was calculated as described26. 2,3,-dioxindolyl alanine and 2-oxindoly 
lalanine were synthesized as described60. Western blot quantification was done 
using either ImageJ software (version 1.46, http://rsbweb.nih.gov/ij/index.html) 
or Image Studio software (version 2, LI-COR Biosciences, Lincoln, NB). The 
HDL-containing lipoprotein fraction (d ≤ 1.21 g ml−1) and LPD fractions 
(d > 1.21 g ml−1) were recovered from plasma or tissue homogenate by sequential 
buoyant density ultracentrifugation using sucrose and D2O to avoid the high 
ionic strength–associated alterations to the protein composition of lipoprotein 
particles observed with KBr use61. Mouse plasma (10–40 µl) was diluted to 
500 µl with 1× PBS buffer (pH 7.0) and 887 µl of sucrose D2O buffer (d = 1.325 
g ml−1; 0.1742 g K2HPO4, 0.1361 g KH2PO4, 0.8182 g NaCl, 111.1 g sucrose and 
100 ml of D2O). The fraction with density less than 1.21 g ml−1 was obtained 
after a 48-h ultracentrifugation at 40,000 r.p.m. at 20 °C (Beckman rotor 50.4Ti; 
8 × 49 mm ultra-clear centrifuge tubes). The lipoprotein fraction (d ≤ 1.21 g ml−1) 
was recovered by slicing the upper 0.25 ml of the tube. HDL cholesterol– 
precipitating reagent (StanBIO Laboratory, 0599) was added to mouse plasma to 
precipitate LDL, and HDL cholesterol was quantified by stable isotope dilution 
gas chromatography mass spectrometry analyses62.
Phage display and affinity maturation of the parental antibody. A single-
chain (scFv) phage display library was constructed using the cDNA derived from 
the 8B5.2 hybridoma cell line using methods described by Barbas et al.63. The 
murine κ variable light chain families VK1 to VK17 and the variable heavy chain 
families VH1 to VH19 were amplified using 26 pairs of family-specific prim-
ers, and then the variable light chain and variable heavy chain sequences were 
‘stitched’ together with a flexible linker (SSGGGGSGGGGGGSSRSS) using over-
lap PCR and cloned into the phagemid pCOMB3 as described63. Recombinant 
phages were prepared from the library with the helper phage M13K07 at a multi-
plicity of infection of ~10. The library was selected using immunotubes (Costar 
#3690) coated with 0.5 ml 25 µg ml−1 Cl.apoA1 (apoA1 exposed to the MPO 
H2O2 Cl− system at a 10:1 molar ratio of H2O2 to apoA1) in 50 mM carbonate 
buffer, pH 9.6, overnight at 4 °C (ref. 64). The rescue-selection-plating cycle 
was repeated three times. For affinity maturation, another phage display scFv 
library was constructed by error-prone PCR followed by passaging the library in 
XL1-red mutator E. coli (Stratagene, La Jolla, CA) four times. Screening of scFv 
by dissociation rate constant (Koff) was performed using real-time biospecific 
interaction analysis based on surface plasmon resonance (SPR) in a Biacore 2000 
(GE Healthcare Life Sciences, Piscataway, NJ). A third library was generated 
by introducing all combinations of mutant residues found in nine individual 
gain-of-function clones into variable regions of the scFv gene. The scFv gene 
was subcloned to a dicistronic baculoviral shuttle vector (a generous gift from 
M. Liang, China CDC) and then recloned into the mammalian expression vec-
tor pcDNA3.1(+) (Life Technologies, Carlsbad, CA., catalog no. V790-20), and 
the dicistronic alleles were expressed in DG44 CHO cells as a chimeric mouse-
human IgG antibody.
SPR. In a Biacore flow cell, approximately 2,000 resonance units (RU) of 
Cl.apoA1 (5 µg ml−1) in 10 mM sodium acetate, pH 4.5, were coupled to a 
CM5 sensor chip. Association and dissociation rates of the original 8B5.2 and 
recombinant affinity-matured antibody were measured under a continuous flow 
of 30 ml min−1 using a concentration range from 0.7 to 1,000 nM. The Ka1 
and Kd1 values were calculated using BIAeveluation software, and sensorgrams 
were fitted by a bivalent model. The apparent KD was calculated from the ratio 
of Kd1/Ka1.
Immunopurification of oxTrp72apoA1. Antibodies were covalently coupled to 
UltraLink Hydrazide resin (Pierce Chemical Co., Rockford, IL) for immunoaffin-
ity isolation of native or oxidized forms of apoA1 from plasma. Before immune-
affinity isolations of apoA1 forms, human albumin was first depleted from the 
plasma as follows. Human plasma was dialyzed in a binding buffer (20 mM 
MOPS, (MOPS: Chem-Impex International, catalog no. 00217) pH 7.0, and 
100 mM NaCl) and diluted fourfold in the binding buffer before it was loaded 
onto a 500-ml column bed of Q Sepharose XL resin (GE Healthcare Life Sciences, 
Piscataway, NJ). Albumin-depleted plasma was collected as flow through (west-
ern blot analyses with various anti-apoA1 mAbs confirmed complete recovery of 
all apoA1 forms (data not shown)). This flow-through fraction was delipidated 
and, to more completely remove contaminating immunoglobulins during the 
immune-affinity isolation step, reduced and denatured with guanidine hydro-
chloride (3 M final, pH 7.8) and dithiothreitol (1 mM final). After the denatured 
fraction was incubated for 1 h at room temperature, the protein was alkylated 
by the addition of iodoacetamide (2.5 mM final) and incubated for 1 h at room 
temperature in a foil-wrapped container. The denatured and alkylated fraction 
was dialyzed against 20 mM Tris-Cl and 150 mM NaCl, and oxTrp72-apoA1 was 
purified from this solution using a covalently coupled r8B5.2 affinity column. 
Total apoA1 was similarly purified using a covalently coupled chicken polyclonal 
IgY that recognizes total apoA1 (anti-HDL IgY microbead slurry; catalog no. 
A20088-G100; Genway Biotech, San Diego, CA).
Cell surface VCAM1 protein expression. Cell surface VCAM1 protein levels 
were determined in BAECs (bovine aortic endothelial cells, Lonza Walkersville, 
Walkersville, MD, catalog no. AC-6001T25). BAECs were starved in DMEM for 
4 h and then incubated with 80 µg of protein per ml of HDL or 80 µg of protein 
per ml of HDL exposed to the MPO H2O2 Cl– system (Cl.HDL) or, where 
indicated, individual protein and plasma for 16 h. After one wash with PBS, 
the cells were fixed in 4% paraformaldehyde for 20 min and blocked in 0.5% 
casein in PBS with 0.02% NaN3 for 4 h. Surface VCAM1 protein was determined 
using goat polyclonal anti-VCAM1 primary antibody (1:4,000, sc-1504, Santa 
Cruz Biotechnology, Santa Cruz, CA) with anti-goat IgG antibody conjugated 
with horseradish peroxidase (1:5,000, sc-2020, Santa Cruz Biotechnology, Santa 
Cruz, CA) as a secondary antibody, detection by SureBlue tetramethylbenzidine 
peroxidase substrate (KPL Inc., Gaithersburg, MD) and measuring absorbance 
at 450 nm on a 96-well plate reader (Spectramax 384 Plus, Molecular Devices, 
Sunnyvale, CA) after the addition of 1 M HCl to stop the reaction.
Confocal immunofluorescent analysis. BAECs (2 × 104 cells per well) were 
inoculated into Lab-Tek Chamber 16-well glass slides (Electron Microscopy 
Sciences, Hatfield, PA) for 16 h. The cells were treated with drugs (Fig. 4f), 
80 µg ml−1 each at 37 °C for 20 min. The cells were then washed with PBS and 
fixed with 4% paraformaldehyde in PBS (15 min, room temperature), permeabi-
lized by immersion in 0.5% Triton X-100 (10 min, room temperature), quenched 
with 100 mM glycine (10 min, room temperature) and blocked in 1% BSA and 
10% normal goat serum in PBS, pH 7.0 (1 h at room temperature). Blocked cells 
were incubated sequentially with primary antibody to NF-κB p65 (Glu498) (3987, 
Cell Signaling Technology, Danvers, MA) diluted (100-fold) in blocking buffer 
(overnight, 4 °C) and secondary antibody goat anti-rabbit IgG-FITC (ab6717-1, 
Abcam, Cambridge, MA) diluted in blocking buffer (100:1, 1 h, room tempera-
ture). Coverslips were mounted onto glass slides using Vectashield DAPI mount-
ing medium (Vector Laboratories Inc., Burlingame, CA). Images were viewed on 
a Leica DMRXE confocal microscope (Leica Microsystems Inc, Buffalo Grove, 
IL) using a 63× oil-immersion objective with a 1.40 numeric aperture. Confocal 
images were acquired using the Leica Confocal Software Version 2.61.
Immunochemistry staining of atherosclerotic plaques. Fresh human aortic 
tissue was obtained as discarded surgical material, both at time of organ harvest 
from transplant donors, and during valve and aortic arch (‘elephant trunk’) 
replacement surgery. Immunohistochemistry of atherosclerotic plaques and 
normal aorta was carried out on fresh-frozen sections. The anti-oxTrp72apoA1 
antibody (r8B5.2 Fab) and polyclonal rabbit anti-human MPO (A0398, Dako 
North America, Inc., Carpinteria, CA) were used at a dilution of 1:400. Mouse 
normal IgG1 (X0931, Dako North America, Inc., Carpinteria, CA) (diluted 400:1) 
was used as the control for antibody staining. The staining procedure followed 
the protocol of the DakoCytomation Envision+ system HRP(AEC) (Dako North 
America, Inc., Carpinteria, CA).
Aortic tissue homogenization. At the time of harvest, all tissues were imme-
diately rinsed in ice-cold PBS supplemented with 100 µM diethylenetriamine 
pentaacetic acid (DTPA) and frozen at −80 °C in argon-sparged buffer A (65 mM 
sodium phosphate, pH 7.4, 100 µM DTPA and 100 µM butylated hydroxytolu-
ene) in gas-tight containers overlaid with argon, which were kept within larger 
argon-flushed sealed containers. At the time of use, samples sealed in gas-tight 
containers were placed in an ice and water bath. Immediately before being com-
plete thawed, tissues were rinsed five times with ice-cold argon-sparged Ca2+ and 
Mg2+-free PBS supplemented with 100 µM DTPA to remove any residual visible 
hemoglobin. The aorta segment was rapidly cleaned of fatty tissues and placed in 
a Petri dish containing ice-cold PBS. The adventitial layer and outer portion of 
the media were carefully peeled from the vessel to give a clean smooth aorta. The 
aorta was rinsed with ice-cold PBS three times and the wet weight of the aorta 
was determined. The tissue was then cut into small pieces (about 3 to 5 mm in 
diameter) in a Petri dish cover on ice. Tissue pieces were suspended in ice-cold 
Ca2+ and Mg2+-free PBS containing a protease inhibitor cocktail. The protease 
cocktail PMSF (1 mM) and Sigma-Aldrich protease inhibitor cocktail (P8340) 
were included in all subsequent solutions used for lipoprotein isolation. Aortic 
tissue was homogenized on ice with a Polytron Tissue Homogenizer (Model PT 
10/35, Brinkman Instruments Inc., Westbury, NY) for 1 min followed by five 
30-s intervals in an ice and water bath. The homogenate was then centrifuged 
at 12,000g for 30 min. The pellet was discarded and the supernatant was stored 
on ice until use. HDL and LPD fractions were separated by ultracentrifugation 
using a sucrose and D2O protocol61.
Indirect ELISA. Nunc MaxSorp ELISA plates (#446612, Thermo Fisher 
Scientific, Waltham, MA) were coated with the indicated purified native or 
oxidized protein (0.2 µg ml−1) in carbonate and bicarbonate buffer, pH 9.6. 
Purified human apoA1, rh-apoA1 and mutant apoA1s were modified by the 
MPO H2O2 Cl− system, the MPO H2O2 NO2− system or multiple other oxidation 
systems, as indicated, at a 10:1 molar ratio of oxidants and apoA1, unless other-
wise specified (the details of the oxidation conditions are described in ref. 25). 
The primary antibody r8B5.2 (50 ng ml−1) (Figs. 1d and 2a,e) was added into the 
5% BSA–blocked ELISA wells and incubated for 1 h at room temperature. The 
plates were then washed with PBS and 0.05% Tween 20 (PBST) four times. Signal 
was detected by Peroxidase AffiniPure Goat Anti-Mouse IgG, F(ab′)2 Fragment 
Specific (1:10,000, code 115-036-006, Jackson ImmunoResearch Laboratories, 
Inc., West Grove, PA).
Competitive ELISA. Nunc MaxSorp ELISA plates (#446612, Thermo Fisher 
Scientific, Waltham, MA) were coated with 0.5 µg ml−1 Cl.apoA1 in carbonate 
and biocarbonate buffer, pH 9.6 (human apoA1 modified by the MPO H2O2 Cl− 
complete oxidative system at a 10:1 molar ratio of H2O2 and apoA1). r8B5.2 
(25 ng ml−1) and peptides were added into the 5% BSA–blocked ELISA wells and 
incubated for 1 h at room temperature. The signal was detected by Peroxidase 
AffiniPure Goat Anti-Mouse IgG, F(ab′)2 Fragment Specific (1:10,000, code 
115-036-006, Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).
Sandwich ELISA. Costar ELISA plates (#3690) were coated with capture 
antibody r8B5.2 (50 µl per well, 7 µg ml−1 in 0.1 M Tris-Cl, pH 8.5) at 4 °C 
overnight. Except for the capture antibody coating process, all other reactions 
were performed at room temperature (20 °C). Coated plates were washed with 
PBS buffer twice, and then washed plates were blocked with 170 µl of blocking 
buffer (1% fish peptone (Fluka Biochemika, 93490), 3% BSA (Sigma, A7030), 
2% poly vinyl alcohol and 0.05% Tween 20 in PBS, pH 7.4) for 2 h. A calibration 
curve was constructed with Cl.apoA1 (8 pM to 8 nM) in sample dilution buffer 
(1% salmon serum and 0.05% Tween 20 in PBS, pH 7.4). Pooled plasma samples 
that had been aliquoted into single-use samples were thawed once and used as 
controls on every plate. Plasma samples were diluted in sample dilution buffer 
(1% salmon serum and 0.05% Tween 20 in PBS, pH 7.4). Diluted samples were 
added into the blocked EIA wells at 50 µl per well and incubated for 45 min. 
The plates were then washed with PBST four times. The detection mAb 10G1.5 
(anti-total apoA125) was diluted (1:40,000) in antibody dilution buffer (0.03% 
BSA (Sigma, A7030) in PBST) and incubated in an EIA well at 50 µl per well for 
30 min. After four washes with PBST, horseradish peroxidase–conjugated neu-
travidin (31001, Pierce Chemical Co., Rockford, IL; 1:10,000 diluted in antibody 
dilution buffer) was added into the ELISA plates (50 µl per well) and incubated 
for 30 min. The ELISA was developed with SureBlue TMB substrate (#52-00-0, 
KPL, Gaithersburg, MD) and the OD450 was determined.
Research subjects. Multiple healthy volunteers donated blood for isolation of 
apoA1, HDL, MPO and other human-derived plasma proteins used through-
out the course of these studies. To examine the relationship between levels 
of oxTrp72-apoA1 and prevalence of CAD and CVD, a cohort of sequential 
consenting subjects (n = 627) presenting to the preventive cardiology outpa-
tient clinic of the Cleveland Clinic was examined as part of an observational 
study called BioBank. Fasting plasma samples and associated clinical data were 
collected at time of patient visit. The CAD definition included adjudicated 
diagnoses of stable or unstable angina, myocardial infarction, angiographic 
evidence of >50% stenosis of one or more major epicardial vessels or history 
of coronary revascularization. Peripheral artery disease (PAD) was defined 
as any evidence of extracoronary atherosclerosis or ankle brachial index <0.9. 
Atherosclerotic CVD was defined as the presence of either CAD or PAD. Patients 
who had experienced a myocardial infarction or stroke within the 1 month 
preceding enrollment were ineligible.
Mouse models. Breeders of all conventional mice C57BL/6 (catalog no. 000664), 
apoA1 homozygous transgenic (catalog no. 001927, C57BL/6-Tg(APOA1)1Rub/J) 
and ApoA1–/– mice (B6.129P2-Apoa1tm1Unc, catalog no. 002055) were obtained 
from Jackson Laboratories. Control mice have a floxed ABCA1 gene (Abca1flox/flox). 
Hepatocyte-specific ABCA1 knockout (Abca1−L/−L; Alb-Cre) Apoa1–/– mice 
on a C57BL/6 background have been described36,65. In our previous study36, 
we documented that wild-type (+/+) and Abca1flox/flox mice have a similar plasma 
lipid phenotype. For the subacute peritonitis model, apoA1 homozygous trans-
genic animals were injected i.p. with zymosan. Plasma was obtained at baseline 
before injection and then serially (1, 2 and 3 d) after injection. OxTrp72-apoA1 
levels in plasma were measured by sandwich ELISA using mAb r8B5.2 as the 
capture antibody and mAb 10G1.5 (anti-total apoA125) as the detection anti-
body. To examine the role of hepatocyte ABCA1 in de novo HDL biogenesis 
in vivo after apoA1 injection, control mice (Abca1flox/flox) and hepatocyte- 
specific ABCA1 KO mice (6–7 weeks old) (Abca1−L/−L; Alb-Cre ) were injected 
with the indicated form of apoA1 s.c. at 400 mg per kg body weight. Blood was 
collected by saphenous vein puncture 1 week before apoA1 injection (baseline) 
and 0.5 h, 1 h, 1.5 h and 2 h after apoA1 injection. ApoA1 KO mice were similarly 
injected s.c. with the indicated form of apoA1 at 400 mg per kg body weight, 
and the appearance and distribution of total human apoA1 and oxTrp72-apoA1 
levels in the blood were monitored both at baseline and 2 h after apoA1 injection. 
All experiments were performed with female mice.
Statistical analyses. Data are presented as the median (first quartile–third 
quartile) for continuous measures and as a number (percentage) for categorical 
measures. Student’s t test or Wilcoxon rank-sum test for continuous variables 
and χ2 test for categorical variables were used to examine the differences 
between participants who had cardiovascular disease events and those who did 
not. Logistic regression models with adjustment for traditional Framingham 
cardiac risk factors (age, sex, hypertension, diabetes mellitus, current or former 
smoker, LDLc and HDLc), triglycerides, apoA1, high sensitivity C-reactive 
protein, MPO, HgbA1c and history of lipid-lowering medicine were used to 
estimate odds ratio and 95% confidence interval for CVD or CAD. All analyses 
were performed using R 2.15.0 (Vienna, Austria), and P < 0.05 was considered 
statistically significant.
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